A diagnosis of Alzheimer’s changes everything.
The brain function begins to decline until it just doesn’t work anymore.
It’s a slow decline that takes a toll not only on the patient but the people who love them.
A new study from a team at University Hospitals hopes to be a first step in reversing the disease. It all started with research in one one of the leading risk factors for Alzheimer’s: traumatic brain injury.
Read all about it HERE
At the start of the COVID-19 pandemic, scientists raced to find treatments for the SARS-CoV-2 virus. When they screened thousands of existing drugs to see if they interfered with the virus, an Ebola drug called remdesivir emerged as one of several antivirals worth further testing.
Clinical trials quickly followed, finding that remdesivir provided modest recovery benefits for high-risk and hospitalized patients, culminating in approval by the end of 2020.
Neuroscientists are borrowing from the same playbook to accelerate the development of new Alzheimer’s treatments. Developing drugs from scratch often takes more than a decade and can cost billions. And in recent years, that’s only yielded two disease-modifying therapies for Alzheimer’s: Leqembi and Kisunla,.
With many experimental dementia drugs failing late in clinical trials, repurposing existing medications approved for other diseases provides another path toward finding new treatments. Because such drugs are already approved for other diseases, they have a well-established safety profile and can move straight to human trials.
In recent years, this strategy has yielded a diverse array of promising hits, from Viagra to rheumatoid arthritis drugs.
Read more HREAt the start of the COVID-19 pandemic, scientists raced to find treatments for the SARS-CoV-2 virus. When they screened thousands of existing drugs to see if they interfered with the virus, an Ebola drug called remdesivir emerged as one of several antivirals worth further testing.
Clinical trials quickly followed, finding that remdesivir provided modest recovery benefits for high-risk and hospitalized patients, culminating in approval by the end of 2020.
Neuroscientists are borrowing from the same playbook to accelerate the development of new Alzheimer’s treatments. Developing drugs from scratch often takes more than a decade and can cost billions. And in recent years, that’s only yielded two disease-modifying therapies for Alzheimer’s: Leqembi and Kisunla,.
With many experimental dementia drugs failing late in clinical trials, repurposing existing medications approved for other diseases provides another path toward finding new treatments. Because such drugs are already approved for other diseases, they have a well-established safety profile and can move straight to human trials.
In recent years, this strategy has yielded a diverse array of promising hits, from Viagra to rheumatoid arthritis drugs.
Read more HERE
Recent research published in Nature Neuroscience provides a detailed cellular map of how physical activity remodels the brain to combat Alzheimer’s disease. By analyzing the genetic activity of individual brain cells, scientists have identified specific molecular pathways that exercise activates to protect memory centers. These findings offer a blueprint for developing future medications that could mimic the neurological benefits of a workout.
Read more HERE
Your daily rhythm may matter more for brain health than previously thought. Older adults with weaker, more disrupted activity patterns were far more likely to develop dementia than those with steady routines. A later daily energy peak was also linked to higher risk. The study points to the body clock as a possible early warning sign for cognitive decline
Read more about it HERE
Alzheimer; News from the web:
BioCog is a brief, self-administered digital test battery that helps to accurately detect cognitive impairment in primary care patients undergoing evaluation for a possible neurodegenerative disease. When combined with blood biomarker tests, the digital test outperformed current standard-of-care assessments of Alzheimer’s disease, supporting a more precise, efficient and timely diagnosis.
Read all about it HERE
Alzheimer; News from the web:
Levels of lithium were significantly reduced in the prefrontal cortex of people with mild cognitive impairment and Alzheimer’s disease (AD).
In a mouse model of AD, a low-dose lithium salt in the diet reversed memory loss and prevented cognitive decline in aging mice.
While more study is needed, lithium replacement could be a potential approach to prevent and treat AD.
Read all about it HERE